Structure Therapeutics Inc.
GPCR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001888886
No open-market purchases or sales by Structure Therapeutics Inc. insiders were filed in the last 90 days; 191 institutions reported holding it in 13F filings for Q2 2026, worth $3.62B in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Structure Therapeutics Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 38 | 48 | +10 |
| Shares | 14.8M | 17.6M | +2.89M (+19.6%) |
| Value | $346.2M | $699.4M | +$353.2M (+102.0%) |
New holders (14)
Institutions that held Structure Therapeutics Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Manufacturers Life Insurance Company, The | 40,631 | $1.69M | 0.00% |
| Avidity Partners Management LP | 37,800 | $1.57M | 0.05% |
| Renaissance Technologies LLC | 32,900 | $1.37M | 0.00% |
| China Universal Asset Management Co., Ltd. | 27,267 | $1.13M | 0.35% |
| Maven Securities LTD | 25,000 | $1.04M | 0.15% |
| Weiss Multi-Strategy Advisers LLC | 15,173 | $631.0K | 0.01% |
| State Street Corp | 11,460 | $476.4K | 0.00% |
| Fred Alger Management, LLC | 10,512 | $437.0K | 0.00% |
| Geode Capital Management, LLC | 10,257 | $426.4K | 0.00% |
| Virtus ETF Advisers LLC | 3,513 | $146.0K | 0.09% |
| Bank of America Corp | 1,684 | $70.0K | 0.00% |
| Barclays PLC | 1,132 | $47.1K | 0.00% |
| Pinpoint Asset Management Ltd | 900 | $37.0K | 0.00% |
| UBS Group AG | 2 | $83 | 0.00% |
Sold out (4)
Institutions that held Structure Therapeutics Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Artal Group S.A. | 75,000 | $1.78M |
| Point72 Middle East FZE | 8,474 | $201.6K |
| Cubist Systematic Strategies, LLC | 805 | $19.2K |
| Morgan Stanley | 11 | $262 |